In order to further improve this percentage and possibly augmenting CAR+ T-cell response to its specific target, we might concentrate anti-CD33.CAR-specific retroviral supernatant administration by increasing the Multiplicity of Infection (MOI)/cells ratio. The gene discussed is CD33; the disease is infection.